Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2016 | Original Article

Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients

Authors: V. Krizkova, M. Dubova, S. Susova, O. Vycital, J. Bruha, M. Skala, V. Liska, O. Daum, P. Soucek

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2016

Abstract

Purpose

This study investigated the prognostic importance of protein expression of ATP-binding cassette (ABC) transporters ABCC10 and ABCC11 in colorectal cancer.

Methods

Protein content of ABCC10 and ABCC11 was assessed in tumor tissue blocks of 140 colorectal cancer patients and associated with survival of patients with regard to 5-fluorouracil-based therapy.

Results

Low ABCC10 protein content in tumors increased hazard ratio of patient's death more than three times in comparison with high ABCC10-expressing tumors (P = 0.004). In contrast, the low ABCC11 content increased the hazard ratio of cancer recurrence in patients almost four times (P = 0.016). Analysis of patients treated with regimens based on 5-fluorouracil revealed that patients with low ABCC11 content in their tumors had shorter disease-free interval than those with higher content (P = 0.024).

Conclusions

The present study shows for the first time that the protein expression of ABCC10 significantly associates with overall survival and the expression of ABCC11 with disease-free interval of colorectal cancer patients and provides strong impulse for further validation of their prognostic value in colorectal cancer.

Available only for authorised users

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMed

Kathawala RJ, Gupta P, Ashby CR Jr et al (2015) The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 18:1–17CrossRefPubMed

Fletcher JI, Haber M, Henderson MJ et al (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147–156CrossRefPubMed

Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162CrossRefPubMed

Cole SPC, Bhardwaj G, Gerlach JH et al (1992) Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258:1650–1654CrossRefPubMed

Doyle LA, Yang W, Abruzzo LV et al (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670CrossRefPubMed

Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R et al (2012) The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27:187–196CrossRefPubMed

Mohelnikova-Duchonova B, Brynychova V, Oliverius M et al (2013) Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and non-neoplastic tissues. Pancreas 42:707–716CrossRefPubMed

Hlavac V, Brynychova V, Vaclavikova R et al (2013) The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics 14:515–529CrossRef

10.

Tonar Z, Witter K, Krizkova V et al (2010) Stereological tools for quantitative microscopy of the aortic wall with focus on the abdominal aortic aneurysm. In: Méndez-Vilas A, Díaz J (eds) Microscopy: science, technology, applications and education. applications in biology and medicine. Formatex Research Centre, Badajoz, 926–935

11.

Budczies J, Klauschen F, Sinn BV et al (2012) Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE 7:e51862CrossRefPubMedPubMedCentral

12.

Hopper E, Belinsky MG, Zeng H et al (2001) Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett 162:181–191CrossRefPubMed

13.

Karatas OF, Guzel E, Duz MB et al (2016) The role of ATP-binding cassette transporter genes in the progression of prostate cancer. Prostate 76:434–444CrossRefPubMed

14.

Chen Z-S, Hopper-Borge E, Belinsky MG et al (2003) Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 63:351–358CrossRefPubMed

15.

Hopper-Borge E, Xu X, Shen T et al (2009) Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 69:178–184CrossRefPubMedPubMedCentral

16.

Bera TK, Lee S, Salvatore G et al (2001) MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 7:509–516PubMedPubMedCentral

17.

Turriziani O, Schuetz JD, Focher F et al (2002) Impaired 2′,3′-dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 368:325–332CrossRefPubMedPubMedCentral

18.

Oguri T, Bessho Y, Achiwa H et al (2007) MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 6:122–127CrossRefPubMed

19.

Yamada A, Ishikawa T, Ota I et al (2013) High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137:773–782CrossRefPubMedPubMedCentral

20.

Magdy T, Arlanov R, Winter S et al (2013) ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Pharmacogenomics 14:1433–1448CrossRefPubMed

21.

Arlanov R, Lang T, Jedlitschky G et al (2016) Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546 M as functionally damaging variant. Pharmacogenomics J 16:193–201CrossRefPubMed

Title: Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients
Authors: V. Krizkova
M. Dubova
S. Susova
O. Vycital
J. Bruha
M. Skala
V. Liska
O. Daum
P. Soucek
Publication date: 01-09-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3114-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab

A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer

Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer

Therapeutic drug monitoring of 5-fluorouracil

Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

Keynote webinar | Spotlight on antibody–drug conjugates in cancer